Drug intelligence / Profile preview

SR750

Development stage: Phase 2
Lead developer: SIMR
Modality: Small Molecules
Administration: Oral

Overview

SR750 is an investigational drug developed by Shanghai SIMR Biotechnology Co., Ltd. It is being evaluated in clinical trials for its pharmacokinetics, safety, and tolerability in healthy subjects, and for its efficacy, safety, and tolerability in patients with trigeminal neuralgia. The drug is administered orally as a tablet. The specific mechanism of action is not disclosed in the provided context.

Other names: Prescription F1

Targets

GABRA5 (Gamma-aminobutyric acid type A receptor subunit alpha-5)

Beyond the preview

Go deeper on SR750.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR750.

Explore the full profile